Overview

Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The purpose of stage 1 of the study is to find out if blood tests can be used to see how the cancer is responding to treatment with pembrolizumab.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
Cancer Research Institute, New York City
Mark Foundation
Mark Foundation for Cancer Research
Personal Genome Diagnostics (PGDx)
Treatments:
Pembrolizumab